First companion diagnostic claim for Illumina's TruSight™ Oncology Comprehensive (EU) test enables targeted therapy with Bayer's VITRAKVI® (larotrectinib) for patients with NTRK fusion cancer
SAN DIEGO, May 24, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer.
If we are to avoid system-wide breakdowns in nature, society and the economy, we need to make six great transitions to thriving. These go beyond the band-aid responses to our global environmental, social and economic challenges that have been so typical of the sustainability agenda over the past 30 years. To be sure, progress has been made, yet the entangled problems of climate change, economic inequality, biodiversity loss and social injustice have been getting worse, not better.
WASHINGTON, May 23, 2022 /3BL Media/ - At the World Economic Forum’s 2022 annual meeting at Davos, Project Last Mile with The Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund) launched its Compendium, Partnering for Health. The document aims to answer the question, “What does it take to build and scale a partnership that translates private sector strengths into the public health system for the global good?”. The Compendium is designed to be shared with other organizations interested in partnering for health.
AUSTIN, Texas, May 20, 2022 /3BL Media/ – In another sign of its commitment to the Austin music industry and its economic impacts, PNC Bank today announced a year-round sponsorship with the Health Alliance for Austin Musicians (HAAM).
We have made huge strides in research across lung cancer types, stages and patient groups
Abderrahim Oukessou, MD, our vice president and Thoracic Cancers Development Lead, sat down with Adam Schoenfeld, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, to discuss how the landscape of lung cancer research has transformed in recent years.
Q: What progress has been made in lung cancer research? How has the latest research changed the meaning of a lung cancer diagnosis compared to five years ago?
Study will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient's cancer, which may influence choice of treatment based on cancer stage and type
SAN DIEGO, May 18, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, and Allegheny Health Network (AHN), an integrated health system serving the Western Pennsylvania area, today announced a collaboration to evaluate the impact of in-house comprehensive genomic profiling (CGP) to enhance patient care.
Scientists at Merck are committed to research and development for people diagnosed with prostate cancer
Almost everyone knows somebody living with prostate cancer.
But the people we know are not just a statistic or a number. They are our partners, parents, children, siblings and friends. They are our loved ones fighting to hang on to their dreams for the future. And that’s who we’re fighting for too — aggressively building our prostate cancer research program day in and day out to help advance new options for patients who need them.
Did you know rates of substance use disorder are rising in the US? The 2020 National Survey on Drug Use and Health reports that 8.3% of American adults, or 20.9 million people, in the United States had a substance use disorder in 2020. Learn more from the full report here: https://bit.ly/37x3bw0
WASHINGTON, May 17, 2022 /3BL Media/ - The Advanced Medical Technology Association (AdvaMed), the world’s largest trade organization representing medical technology device developers and manufacturers, today announced the first-ever